ArticleJACC. Advances2024
Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA.
Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Recent approaches in the sensing strategy for the detection of cardiovascular disease biomarkers.RSC advances · 2026Review
- Lipoprotein metabolism and inflammation in healthy young subjects - exploring the postprandial and postabsorptive phases following intake of a standardized meal.Atherosclerosis plus · 2026Article
- Metabolomic Signatures of Inflammation in Chronic Kidney Disease.Kidney medicine · 2026Article
- Human biomarker navigator.iMeta · 2026Review
- Article
- Data Consistency and Interpretation of Interleukin-6 and Cardiovascular Outcomes in MESA.JACC. Advances · 2026Article
- Short-term mTOR inhibition by rapamycin improves cardiac and endothelial function in older men: a proof-of concept pilot study.GeroScience · 2026Article
- Review
- Maternal and cord-blood inflammatory markers and BDNF in diabetic vs. non-diabetic pregnancies.Scientific reports · 2026Article
- Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.Journal of lipid and atherosclerosis · 2026Review
- The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis.European journal of preventive cardiology · 2026Article
- Inflammatory and cholesterol risks and rates of major cardiovascular events among patients with atherosclerotic cardiovascular disease in routine care.European heart journal open · 2026Article
- Echocardiography and inflammatory biomarkers for predicting mortality and major adverse cardiovascular events in type 1 diabetes.Cardiovascular diabetology · 2026Article
- Role of Interleukin-6 in Atherothrombosis and Myocardial Infarction.Current atherosclerosis reports · 2026Review
- Beyond the Usual Suspects: A Narrative Review of High-Yield Non-Traditional Risk Factors for Atherosclerosis.Journal of clinical medicine · 2026Review
- Managing mild autonomous cortisol secretion (MACS): evaluating the role of medical treatment.Frontiers in endocrinology · 2026Article
- The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Daily intake of a lycopene-rich juice is associated with reductions in inflammatory markers but not increases in skin carotenoids in a pilot study among participants with obesity.BMC nutrition · 2025Article
- Relationship between interleukin-6, coronary artery calcium and risk of heart failure: Insights from MESA.American journal of preventive cardiology · 2025Article
- The effect of dapagliflozin in Chinese elderly patients with heart failure.Journal of geriatric cardiology : JGC · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Background: Elevated interleukin (IL)-6 levels have been linked to adverse outcomes in patients with and without baseline cardiovascular disease (CVD). Objectives: The purpose of this study was to examine the association between circulating IL-6 levels and CVD events without baseline CVD across racial and ethnic groups. Methods: We conducted an observational analysis utilizing the MESA (Multi-Ethnic Study of Atherosclerosis), a multicenter, prospective community-based study of CVD at baseline from four racial and ethnic groups. IL-6 levels were measured at the time of enrollment (visit 1) and were divided into 3 terciles. Patient baseline characteristics and outcomes, including all-cause mortality, CV mortality, heart failure, and non-CV mortality, were included. Cox proportional hazard regression models were used to assess associations between IL-6 levels and study outcomes with IL-6 tercile 1 as reference. Results: Of 6,622 individuals, over half were women (53%) with a median age of 62 (IQR: 53-70) years. Racial and ethnic composition was non-Hispanic White (39%) followed by African American (27%), Hispanic (22%), and Chinese American (12%). Compared to tercile 1, participants with IL-6 tercile 3 had a higher adjusted risk of and all-cause mortality (HR: 1.98 [95% CI: 1.67-2.36]), CV mortality (HR: 1.55 [95% CI: 1.05-2.30]), non-CV mortality (HR: 2.05 [95% CI: 1.65-2.56]), and heart failure (HR: 1.48 [95% CI: 0.99-2.19]). When tested as a continuous variable, higher levels of IL-6 were associated with an increased risk of all individual outcomes. Compared to non-Hispanic White participants, the unadjusted and adjusted risk of all outcomes across all races and ethnicities was similar across all IL-6 terciles. Conclusions: High levels of circulating IL-6 are associated with worse CV outcomes and increased all-cause mortality consistently across all racial and ethnic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.